Trifluoroacetic acid-mediated synthesis of xanthene constructs and their extensive anti-tuberculosis evaluation†

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2024-01-12 DOI:10.1039/D3MD00518F
Bisma Teli, Mohamad Mosa Mubarak, Zahoor Ahmad and Bilal A. Bhat
{"title":"Trifluoroacetic acid-mediated synthesis of xanthene constructs and their extensive anti-tuberculosis evaluation†","authors":"Bisma Teli, Mohamad Mosa Mubarak, Zahoor Ahmad and Bilal A. Bhat","doi":"10.1039/D3MD00518F","DOIUrl":null,"url":null,"abstract":"<p >A diverse range of 9-substituted 1,8-dioxohexahydroxanthenes was conceptualized and synthesized through a TFA-mediated approach in near quantitative yields without the use of column chromatography. From a series of 25 compounds, we found that compounds <strong>14c</strong> and <strong>14r</strong> exhibited promising anti-tuberculosis potential against avirulent and virulent strains of <em>Mycobacterium tuberculosis</em> with a Minimal Inhibitory Concentration (MIC) of 8 μg ml<small><sup>−1</sup></small>, achieving 99% bactericidal activity at the same concentration. This series of compounds was found to be inactive against common Gram-positive and Gram-negative pathogens, indicating that the activity is mycobacteria-specific. Since the strategies for treating tuberculosis employ a combinatorial therapy, we tested and observed that the two lead compounds displayed synergistic behavior with known anti-TB drugs (ATDs) and a significant (16–32 fold) decrease in MIC values of both leads was observed in combination with either RIF or INH. Interestingly the lead molecule <strong>14c</strong> displayed only time-dependent kill kinetics and sterilized the whole culture of <em>Mycobacterium tuberculosis</em> H37Rv in just 48 hours.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":null,"pages":null},"PeriodicalIF":3.5970,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d3md00518f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

A diverse range of 9-substituted 1,8-dioxohexahydroxanthenes was conceptualized and synthesized through a TFA-mediated approach in near quantitative yields without the use of column chromatography. From a series of 25 compounds, we found that compounds 14c and 14r exhibited promising anti-tuberculosis potential against avirulent and virulent strains of Mycobacterium tuberculosis with a Minimal Inhibitory Concentration (MIC) of 8 μg ml−1, achieving 99% bactericidal activity at the same concentration. This series of compounds was found to be inactive against common Gram-positive and Gram-negative pathogens, indicating that the activity is mycobacteria-specific. Since the strategies for treating tuberculosis employ a combinatorial therapy, we tested and observed that the two lead compounds displayed synergistic behavior with known anti-TB drugs (ATDs) and a significant (16–32 fold) decrease in MIC values of both leads was observed in combination with either RIF or INH. Interestingly the lead molecule 14c displayed only time-dependent kill kinetics and sterilized the whole culture of Mycobacterium tuberculosis H37Rv in just 48 hours.

Abstract Image

Abstract Image

三氟乙酸介导的氧杂蒽构建体合成及其广泛的抗结核评价
通过反式脂肪酸介导的方法,我们构思并合成了一系列不同的 9-取代型 1,8-二氧代六氢蒽,其产量接近定量,无需使用柱层析。从一系列 25 个化合物中,我们发现化合物 14c 和 14r 对无毒和有毒株结核分枝杆菌具有良好的抗结核潜力,最低抑菌浓度(MIC)为 8 μg ml-1,在相同浓度下杀菌活性达到 99%。研究发现,这一系列化合物对常见的革兰氏阳性和革兰氏阴性病原体均无活性,表明其活性具有分枝杆菌特异性。由于治疗结核病的策略采用的是组合疗法,我们测试并观察到这两种先导化合物与已知的抗结核药物(ATDs)具有协同作用,与 RIF 或 INH 联用时,两种先导化合物的 MIC 值均显著降低(16-32 倍)。有趣的是,先导分子 14c 只显示出时间依赖性杀灭动力学,仅在 48 小时内就能杀灭整个结核分枝杆菌 H37Rv 培养物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信